Table 2 Ongoing clinical trials of anti-HER2 monoclonal antibodies
Drug | Identifier | Disease | Phase | Treatment arms |
|---|---|---|---|---|
Trastuzumab | NCT01367002 | HER2+ uterine serous cancer | 2 | a. Carboplatin + paclitaxel + trastuzumab b. Carboplatin + paclitaxel |
Trastuzumab | NCT01196390 | Esophageal cancer | 3 | a. Radiation + chemotherapy + trastuzumab b. Radiation + chemotherapy |
Trastuzumab | NCT01325207 | CNS progression HER2+ breast cancer | 1/2 | Intravenous trastuzumab |
Trastuzumab | NCT02030561 | HER2+ breast and gastric cancer | 1/2 | Trastuzumab + NK cells |
Trastuzumab | NCT02598310 | HER2+/ER− operable breast cancer | 2 | Nab-paclitaxel + trastuzumab |
Trastuzumab | NCT01340430 | HER2+ breast cancer | 2 | FEC + paclitaxel + trastuzumab |
Trastuzumab | NCT01785420 | HER2+ operable breast cancer | 3 | a. Trastuzumab b. Placebo |
Trastuzumab | NCT02152943 | HR−/HER2+ advanced cancers | 1 | Everolimus + letrozole + trastuzumab |
Trastuzumab | NCT01950182 (SYSUCC-002) | Luminal B2 breast cancer | 3 | a. Trastuzumab + chemotherapy b. Endocrine therapy + trastuzumab |
Trastuzumab | NCT01873833 | HER2+ metastatic breast cancer | 2 | Chemotherapy + lapatinib ditosylate + trastuzumab |
Pertuzumab | NCT01996267 (TRAIN-2) | HER2+ breast cancer | 3 | a. FEC-TÂ +Â pertuzumab b. PTCÂ +Â pertuzumab |
Pertuzumab | NCT01572038 (PERUSE) | HER2+ breast cancer | 3 | Pertuzumab + trastuzumab + taxane |
Pertuzumab | NCT02229149 | HER2+ metastatic breast cancer | 2 | a. Chemotherapy + trastuzumab + pertuzumab b. Chemotherapy + trastuzumab |
Pertuzumab | NCT02896855 | HER2+ metastatic breast cancer | 3 | a. Pertuzumab + trastuzumab + docetaxel b. Placebo + trastuzumab + docetaxel |
Pertuzumab | NCT02625441 | HER2+ early breast cancer | 3 | a. Pertuzumab + trastuzumab + docetaxel b. Trastuzumab + docetaxel |
Trastuzumab Pertuzumab | NCT02139358 | HER2+ metastatic breast cancer | 1/2 | Gemcitabine + trastuzumab + pertuzumab |
Trastuzumab Pertuzumab | NCT01774786 | HER2+ gastric or gastroesophageal junction cancer | 3 | Pertuzumab + trastuzumab + chemotherapy |
Trastuzumab Pertuzumab | NCT02536339 | CNS progression HER2+ breast cancer | 2 | Pertuzumab + high-dose trastuzumab |
Trastuzumab Pertuzumab | NCT02598427 | CNS progression HER2+ breast cancer | 1 | Intrathecal + pertuzumab + trastuzumab |
Trastuzumab Pertuzumab | NCT02581462 | HER2+ gastric or gastroesophageal cancer | 2/3 | a. FLOT b. FLOT + trastuzumab + pertuzumab |
Trastuzumab Pertuzumab | NCT02436993 | Breast cancer | 2 | a. Carboplatin + paclitaxel + bevacizumab (HER2−) b. Carboplatin + paclitaxel + trastuzumab + pertuzumab (HER2+) |
Trastuzumab Pertuzumab | NCT02411344 | HER2+/HR+ breast cancer | 2 | Pertuzumab + trastuzumab + letrozole |
T-DM1 Pertuzumab | NCT02326974 | HER2+ breast cancer | 2 | T-DM1Â +Â pertuzumab |
T-DM1 | NCT02414646 | HER2+ breast cancer | 2 | T-DM1 |
T-DM1 | NCT02675829 | HER2 amplified or mutant cancers | 2 | T-DM1 |
T-DM1 | NCT01702571 | HER2+ locally advanced/metastatic breast cancer | 3 | T-DM1 |
T-DM1 | NCT02289833 | HER2+ locally advanced/metastatic NSCLC | 2 | T-DM1 |
T-DM1 | NCT01966471 | HER2+ primary breast cancer | 3 | a. T-DM1 + pertuzumab b. Trastuzumab + pertuzumab + taxane |
T-DM1 | NCT01772472 (KATHERINR) | HER2+ breast cancer | 3 | a. T-DM1 b. Trastuzumab |
MGAH22 | NCT01148849 | HER2+ cancers | 1 | MGAH22 (margetuximab) |
MGAH22 | NCT02492711 (SOPHIA) | HER2+ metastatic breast cancer | 3 | a. Margetuximab + chemotherapy b. Trastuzumab + chemotherapy |
MGAH22 | NCT02689284 | HER2+ gastric or gastroesophageal junction cancer | 1/2 | Margetuximab + pembrolizumab |
XMT-1522 | NCT02952729 | HER2+ breast cancer, NSCLC and gastric cancer | 1 | XMT-1522 |
DS-8201a | NCT02564900 | Advanced solid tumors | 1 | DS-8201a |
SYD985 | NCT02277717 | Locally advanced/metastatic solid tumors | 1 | SYD985 |